Metachromatic leukodystrophy (MLD) is a rare inherited lysosomal storage disorder that results from a deficiency of the arylsulfatase A (ARSA) enzyme and leads to progressive neurodegeneration and demyelination. Due to its narrow pre-symptomatic window of opportunity for disease-modifying therapies, the implementation of newborn screening (NBS) for MLD seems crucial and the incorporation of MLD screening into existing NBS programs is required. In many NBS programs, DNA-based assays have already been established, for instance to screen for severe combined immunodeficiency, sickle cell disease, or spinal muscular atrophy. Utilizing these DNA eluates, we established high-multiplex mutation testing (HMMT), a novel DNA-based method, as a genetic first-tier to screen for MLD. By multiplex allele-specific amplification, the assay detects thirteen frequent ARSA variants within the European population identifying newborns with MLD with a modelled, gnomAD-based sensitivity of approximately 92%. Anonymized DNA eluates from 3,078 newborns were tested retrospectively. Variants were identified in nine samples (0.3%) confirmed by an allele-specific differentiation assay and next-generation sequencing. HMMT proved capable to identify frequent ARSA variants as a genetic first-tier test, while panel composition and achievable sensitivity remain to be tested and optimised in a real-world cohort. When biochemical testing cannot be implemented as first tier screening, our approach might be useful to set up as simple screening algorithm for MLD.